2024-10-11 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

**1. Performance Overview**

Amgen Inc (AMGN) is a biotechnology company that develops, manufactures, and markets a broad range of human therapeutics. 

**Cumulative Returns:**

* AMGN: 80.3%
* S&P 500 (VOO): 134.82%

**Relative Performance:**

* **Current Performance:**  AMGN has underperformed the S&P 500 by **-53.51%** in terms of cumulative returns.
* **Historical Context:**  This underperformance represents a **32.5%** position within the historical range of the relative performance of AMGN compared to the S&P 500, which spans from **-79.13% to 7.29%**.

**2. Recent Price Movement**

* **Closing Price:** $322.41
* **5-Day Moving Average:** $318.94
* **20-Day Moving Average:** $326.08
* **60-Day Moving Average:** $327.77

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 38.68 - This suggests that AMGN is currently in the oversold territory.
* **PPO (Percentage Price Oscillator):** -0.24 - This indicates that the price momentum is currently negative.
* **Delta_Previous_Relative_Divergence:** -12.92 - This shows a short-term downward trend in the relative performance of AMGN compared to the S&P 500.
* **Expected Return:** 0.0% - This suggests that based on current data, there is no expected excess return over the S&P 500 for a 5-year investment period.

**4. Recent Earnings and Outlook**

| Date         | EPS      | Revenue |
|--------------|----------|---------|
| 2024-08-07 | 1.39     | 8.39 B$ |
| 2024-05-03 | -0.21    | 7.45 B$ |
| 2023-10-31 | 3.23     | 6.90 B$ |
| 2023-08-04 | 2.58     | 6.99 B$ |

The most recent earnings report for the quarter ending August 7th, 2024 showed an EPS of 1.39, surpassing the analyst estimates of 1.22. Revenue came in at 8.39 billion dollars, exceeding the consensus estimate of 8.25 billion dollars.

**5. News and Recent Issues**

* **Recent Market Outlook:** AMGN's stock price has been affected by recent market volatility. The biotechnology sector has been impacted by rising interest rates and concerns about economic growth.
* **Analyst Opinions:**  Analysts are currently divided on the future of AMGN stock, with some analysts holding a bullish outlook due to its strong pipeline of drugs and a strong balance sheet. However, others are more cautious about the company's growth prospects.
* **Performance Highlights:** AMGN has experienced challenges recently, including increased competition in the biosimilars market and declining sales for some of its key products. Despite these challenges, the company has a robust product portfolio and continues to invest in research and development.

**6. Summary**

AMGN has underperformed the S&P 500 in the past, and its recent performance has been lackluster, despite a positive latest earnings report.  Technical indicators suggest that the stock is currently in oversold territory, and the expected return is relatively low.  Although the company faces challenges, its robust product portfolio and ongoing investment in research and development might potentially lead to future growth. Investors should carefully consider the company's current performance, challenges, and future prospects before making any investment decisions.

**7. Disclaimer:**

This report is for informational purposes only and should not be considered investment advice. It is important to conduct your own research and consult with a financial advisor before making any investment decisions.
